Literature DB >> 11707575

Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein.

R V Kondratov1, P G Komarov, Y Becker, A Ewenson, A V Gudkov.   

Abstract

By screening a chemical library for the compounds protecting cells from adriamycin (Adr), a series of small molecules was isolated that interfered with the accumulation of Adr in mouse fibroblasts by enhancing efflux of the drug. Isolated compounds also stimulated efflux of Rhodamine 123 (Rho-123), another substrate of multidrug transporters. Stimulation of drug efflux was detectable in the cells expressing P-glycoprotein (P-gp), but not in their P-gp-negative variants, and was completely reversible by the P-gp inhibitors. A dramatic stimulation of P-gp activity against Adr and Rho-123 by the identified compounds was accompanied by suppression of P-gp-mediated efflux of other substrates, such as Taxol (paclitaxel) or Hoechst 33342, indicating that they act as modulators of substrate specificity of P-gp. Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates. The relative effect of P-gp modulators against different substrates varied among the isolated compounds that can be used as fine tools for analyzing mechanisms of drug selectivity of P-gp. These results raise the possibility of a rational control over cell sensitivity to drugs and toxins through modulation of P-gp activity by small molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707575      PMCID: PMC61170          DOI: 10.1073/pnas.241314798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques.

Authors:  T W Loo; D M Clarke
Journal:  Biochim Biophys Acta       Date:  1999-12-06

2.  Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system.

Authors:  C A Hrycyna; M Ramachandra; I Pastan; M M Gottesman
Journal:  Methods Enzymol       Date:  1998       Impact factor: 1.600

Review 3.  The physiological function of drug-transporting P-glycoproteins.

Authors:  A H Schinkel
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

Review 4.  Multidrug resistant proteins.

Authors:  P Borst
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

5.  Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.

Authors:  A B Shapiro; V Ling
Journal:  Eur J Biochem       Date:  1997-11-15

Review 6.  Search for specific inhibitors of multidrug resistance in cancer.

Authors:  B Sarkadi; M Müller
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

7.  Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.

Authors:  A B Shapiro; K Fox; P Lam; V Ling
Journal:  Eur J Biochem       Date:  1999-02

Review 8.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

9.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

10.  Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships.

Authors:  J Ferté; J M Kühnel; G Chapuis; Y Rolland; G Lewin; M A Schwaller
Journal:  J Med Chem       Date:  1999-02-11       Impact factor: 7.446

View more
  19 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

Review 2.  Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  AAPS J       Date:  2009-06-06       Impact factor: 4.009

3.  Drug transport into the central nervous system: using newer findings about the blood-brain barriers.

Authors:  William A Banks
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

Review 4.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

5.  Proposed mechanistic description of dose-dependent BDE-47 urinary elimination in mice using a physiologically based pharmacokinetic model.

Authors:  Claude Emond; J Michael Sanders; Daniele Wikoff; Linda S Birnbaum
Journal:  Toxicol Appl Pharmacol       Date:  2013-09-19       Impact factor: 4.219

6.  Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.

Authors:  Sinjan De; Donald W Miller; Dennis H Robinson
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 7.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

8.  Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.

Authors:  Catherine A Burkhart; Fujiko Watt; Jayne Murray; Marina Pajic; Anatoly Prokvolit; Chengyuan Xue; Claudia Flemming; Janice Smith; Andrei Purmal; Nadezhda Isachenko; Pavel G Komarov; Katerina V Gurova; Alan C Sartorelli; Glenn M Marshall; Murray D Norris; Andrei V Gudkov; Michelle Haber
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  ABC transporters in cancer: more than just drug efflux pumps.

Authors:  Jamie I Fletcher; Michelle Haber; Michelle J Henderson; Murray D Norris
Journal:  Nat Rev Cancer       Date:  2010-01-15       Impact factor: 60.716

10.  Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.

Authors:  Fa Yun Zhang; Gang Jun Du; Ling Zhang; Chun Ling Zhang; Wan Liang Lu; Wei Liang
Journal:  Pharm Res       Date:  2008-12-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.